vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and MATTEL INC (MAT). Click either name above to swap in a different company.

MATTEL INC is the larger business by last-quarter revenue ($862.2M vs $487.7M, roughly 1.8× CLOVER HEALTH INVESTMENTS, CORP.). MATTEL INC runs the higher net margin — 7.1% vs -10.1%, a 17.2% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 4.3%). CLOVER HEALTH INVESTMENTS, CORP. produced more free cash flow last quarter ($-69.0M vs $-88.1M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -10.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Mattel Films was the film production division of American toy and entertainment company Mattel that operated from September 6, 2018 to June 2, 2025. It succeeded Mattel Playground Productions, which was formed on October 16, 2013 as part of Mattel Global Brands, a unified media structural and strategy unit, as itself the successor to Mattel Entertainment and Mattel Studios, Mattel's prior entertainment brands/banners.

CLOV vs MAT — Head-to-Head

Bigger by revenue
MAT
MAT
1.8× larger
MAT
$862.2M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+40.4% gap
CLOV
44.7%
4.3%
MAT
Higher net margin
MAT
MAT
17.2% more per $
MAT
7.1%
-10.1%
CLOV
More free cash flow
CLOV
CLOV
$19.1M more FCF
CLOV
$-69.0M
$-88.1M
MAT
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-10.6%
MAT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
MAT
MAT
Revenue
$487.7M
$862.2M
Net Profit
$-49.3M
$61.0M
Gross Margin
44.9%
Operating Margin
-10.1%
Net Margin
-10.1%
7.1%
Revenue YoY
44.7%
4.3%
Net Profit YoY
-123.2%
251.4%
EPS (diluted)
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
MAT
MAT
Q1 26
$862.2M
Q4 25
$487.7M
$1.8B
Q3 25
$496.6M
$1.7B
Q2 25
$477.6M
$1.0B
Q1 25
$462.3M
$826.6M
Q4 24
$337.0M
$1.6B
Q3 24
$331.0M
$1.8B
Q2 24
$356.3M
$1.1B
Net Profit
CLOV
CLOV
MAT
MAT
Q1 26
$61.0M
Q4 25
$-49.3M
$106.2M
Q3 25
$-24.4M
$278.4M
Q2 25
$-10.6M
$53.4M
Q1 25
$-1.3M
$-40.3M
Q4 24
$-22.1M
$140.9M
Q3 24
$-9.2M
$372.4M
Q2 24
$7.4M
$56.9M
Gross Margin
CLOV
CLOV
MAT
MAT
Q1 26
44.9%
Q4 25
45.9%
Q3 25
50.0%
Q2 25
50.9%
Q1 25
49.4%
Q4 24
50.7%
Q3 24
24.5%
53.1%
Q2 24
30.3%
49.2%
Operating Margin
CLOV
CLOV
MAT
MAT
Q1 26
Q4 25
-10.1%
8.0%
Q3 25
-4.9%
21.9%
Q2 25
-2.2%
7.7%
Q1 25
-0.3%
-6.4%
Q4 24
-6.4%
9.6%
Q3 24
-2.7%
26.5%
Q2 24
2.0%
7.7%
Net Margin
CLOV
CLOV
MAT
MAT
Q1 26
7.1%
Q4 25
-10.1%
6.0%
Q3 25
-4.9%
16.0%
Q2 25
-2.2%
5.2%
Q1 25
-0.3%
-4.9%
Q4 24
-6.6%
8.6%
Q3 24
-2.8%
20.2%
Q2 24
2.1%
5.3%
EPS (diluted)
CLOV
CLOV
MAT
MAT
Q1 26
$0.20
Q4 25
$0.32
Q3 25
$0.88
Q2 25
$0.16
Q1 25
$-0.12
Q4 24
$0.40
Q3 24
$1.09
Q2 24
$0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
MAT
MAT
Cash + ST InvestmentsLiquidity on hand
$78.3M
$866.0M
Total DebtLower is stronger
$2.3B
Stockholders' EquityBook value
$308.7M
$2.1B
Total Assets
$541.0M
$6.3B
Debt / EquityLower = less leverage
1.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
MAT
MAT
Q1 26
$866.0M
Q4 25
$78.3M
$1.2B
Q3 25
$691.9M
Q2 25
$870.5M
Q1 25
$1.2B
Q4 24
$194.5M
$1.4B
Q3 24
$288.0M
$723.5M
Q2 24
$254.8M
$722.4M
Total Debt
CLOV
CLOV
MAT
MAT
Q1 26
$2.3B
Q4 25
$2.3B
Q3 25
$2.3B
Q2 25
$2.3B
Q1 25
$2.3B
Q4 24
$2.3B
Q3 24
$2.3B
Q2 24
$2.3B
Stockholders' Equity
CLOV
CLOV
MAT
MAT
Q1 26
$2.1B
Q4 25
$308.7M
$2.2B
Q3 25
$340.9M
$2.3B
Q2 25
$344.2M
$2.2B
Q1 25
$336.1M
$2.1B
Q4 24
$341.1M
$2.3B
Q3 24
$342.2M
$2.3B
Q2 24
$324.9M
$2.0B
Total Assets
CLOV
CLOV
MAT
MAT
Q1 26
$6.3B
Q4 25
$541.0M
$6.6B
Q3 25
$559.7M
$6.6B
Q2 25
$575.0M
$6.2B
Q1 25
$583.7M
$6.2B
Q4 24
$580.7M
$6.5B
Q3 24
$653.0M
$6.5B
Q2 24
$674.2M
$5.9B
Debt / Equity
CLOV
CLOV
MAT
MAT
Q1 26
1.11×
Q4 25
1.04×
Q3 25
1.03×
Q2 25
1.08×
Q1 25
1.10×
Q4 24
1.03×
Q3 24
1.01×
Q2 24
1.18×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
MAT
MAT
Operating Cash FlowLast quarter
$-66.9M
Free Cash FlowOCF − Capex
$-69.0M
$-88.1M
FCF MarginFCF / Revenue
-14.1%
-10.2%
Capex IntensityCapex / Revenue
0.4%
7.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
MAT
MAT
Q1 26
Q4 25
$-66.9M
$796.6M
Q3 25
$12.1M
$72.0M
Q2 25
$5.4M
$-300.1M
Q1 25
$-16.3M
$24.8M
Q4 24
$34.8M
$862.1M
Q3 24
$50.0M
$155.8M
Q2 24
$44.8M
$-252.9M
Free Cash Flow
CLOV
CLOV
MAT
MAT
Q1 26
$-88.1M
Q4 25
$-69.0M
Q3 25
$11.4M
Q2 25
$4.8M
Q1 25
$-16.5M
Q4 24
$33.3M
Q3 24
$49.6M
Q2 24
$44.4M
FCF Margin
CLOV
CLOV
MAT
MAT
Q1 26
-10.2%
Q4 25
-14.1%
Q3 25
2.3%
Q2 25
1.0%
Q1 25
-3.6%
Q4 24
9.9%
Q3 24
15.0%
Q2 24
12.5%
Capex Intensity
CLOV
CLOV
MAT
MAT
Q1 26
7.6%
Q4 25
0.4%
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.0%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Cash Conversion
CLOV
CLOV
MAT
MAT
Q1 26
Q4 25
7.50×
Q3 25
0.26×
Q2 25
-5.62×
Q1 25
Q4 24
6.12×
Q3 24
0.42×
Q2 24
6.04×
-4.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons